Skip to main content
. 2020 Jun 30;13:6303–6314. doi: 10.2147/OTT.S250412

Figure 5.

Figure 5

GRHL2 expression increased cisplatin-resistance in vivo. (A, B) The growth in mice of tumors developed from SKOV3/DDP-shGRHL2 or SKOV3/DDP-shcontrol cells were treated with cisplatin (3.0 mg/kg six times with a gap of 3 days). **;P< 0.01 vs SKOV3/DDP -shcontrol. (C, D) The growth in mice of tumors developed from SKOV3-GRHL2 or SKOV3-control cells were treated with cisplatin (3.0 mg/kg six times with a gap of 3 days). **P< 0.01 vs SKOV3-control cells.

Note: n=3 per group.